In CAR-T therapy, granzyme B cleaves GSDME in tumor cells, which triggers macrophage activation of caspase-1/GSDMD and leads to IL-1β/IL-6 release [10, 135] (Fig. 5). The gene discussed is CASP1; the disease is neoplasm.